March Pdufa dates are set for relatlimab as well as Akebia’s vadadustat, while Amylyx’s ALS drug heads for a panel.
But whether data on the novel anaemia pill are clean enough to dispel wider FDA toxicity concerns is hard to call.
The group will have to pivot to a heart surgery setting, but the omens here are not good. Meanwhile, Vifor’s run of bad luck continues.
But winning EU approval for the novel anaemia pill was not straightforward, the Japanese firm says.
Walmsley wins some breathing space but, for ambitious new growth targets to be met, the pipeline must start delivering.